Twist Bioscience Corporation Debt Securities, Available-for-sale, Unrealized Gain
Twist Bioscience Corporation (TWST) reported Debt Securities, Available-for-sale, Unrealized Gain of $1.00 thousand for the 12-month period ending 2021-09-30, per its 10-K filed 2021-11-23.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2021-11-23
- Twist Bioscience Corporation debt securities, available-for-sale, unrealized gain for fiscal 2021 was $1.00K, a 93.33% decline from fiscal 2020.
- Twist Bioscience Corporation debt securities, available-for-sale, unrealized gain for fiscal 2020 was $15.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|
| 2021-09-30 | $1.00K 10-K · filed 2021-11-23 |
| 2020-09-30 | $15.00K 10-K · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |